Kok M - Search Results

1

Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer.

Holm C, Kok M, Michalides R, Fles R, Koornstra RH, Wesseling J, Hauptmann M, Neefjes J, Peterse JL, Stål O, Landberg G, Linn SC. Holm C, et al. Among authors: kok m. J Pathol. 2009 Feb;217(3):372-9. doi: 10.1002/path.2455. J Pathol. 2009. PMID: 18991335

2

Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.

Kok M, Linn SC, Van Laar RK, Jansen MP, van den Berg TM, Delahaye LJ, Glas AM, Peterse JL, Hauptmann M, Foekens JA, Klijn JG, Wessels LF, Van't Veer LJ, Berns EM. Kok M, et al. Breast Cancer Res Treat. 2009 Jan;113(2):275-83. doi: 10.1007/s10549-008-9939-y. Epub 2008 Mar 4. Breast Cancer Res Treat. 2009. PMID: 18311582

3

Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer.

Kok M, Koornstra RH, Margarido TC, Fles R, Armstrong NJ, Linn SC, Van't Veer LJ, Weigelt B. Kok M, et al. J Pathol. 2009 Jul;218(3):316-26. doi: 10.1002/path.2544. J Pathol. 2009. PMID: 19353633

4

Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer.

Roepman P, Horlings HM, Krijgsman O, Kok M, Bueno-de-Mesquita JM, Bender R, Linn SC, Glas AM, van de Vijver MJ. Roepman P, et al. Among authors: kok m. Clin Cancer Res. 2009 Nov 15;15(22):7003-11. doi: 10.1158/1078-0432.CCR-09-0449. Epub 2009 Nov 3. Clin Cancer Res. 2009. PMID: 19887485

5

Estrogen receptor-alpha phosphorylation at serine-118 and tamoxifen response in breast cancer.

Kok M, Holm-Wigerup C, Hauptmann M, Michalides R, Stål O, Linn S, Landberg G. Kok M, et al. J Natl Cancer Inst. 2009 Dec 16;101(24):1725-9. doi: 10.1093/jnci/djp412. J Natl Cancer Inst. 2009. PMID: 19940281 Clinical Trial.

6

PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer.

Kok M, Zwart W, Holm C, Fles R, Hauptmann M, Van't Veer LJ, Wessels LF, Neefjes J, Stål O, Linn SC, Landberg G, Michalides R. Kok M, et al. Breast Cancer Res Treat. 2011 Jan;125(1):1-12. doi: 10.1007/s10549-010-0798-y. Epub 2010 Mar 9. Breast Cancer Res Treat. 2011. PMID: 20213082 Clinical Trial.

7

Gene expression profiles of the oestrogen receptor in breast cancer.

Kok M, Linn SC. Kok M, et al. Neth J Med. 2010 Oct;68(10):291-302. Neth J Med. 2010. PMID: 21071774 Free article. Review.

8

Estrogen receptor phenotypes defined by gene expression profiling.

Kok M, Linn S, van de Vijver M. Kok M, et al. Cancer Treat Res. 2009;147:1-18. doi: 10.1007/978-0-387-09463-2_11. Cancer Treat Res. 2009. PMID: 21461831 No abstract available.

9

The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.

van Schaik RH, Kok M, Sweep FC, van Vliet M, van Fessem M, Meijer-van Gelder ME, Seynaeve C, Lindemans J, Wesseling J, Van 't Veer LJ, Span PN, van Laarhoven H, Sleijfer S, Foekens JA, Linn SC, Berns EM. van Schaik RH, et al. Among authors: kok m. Pharmacogenomics. 2011 Aug;12(8):1137-46. doi: 10.2217/pgs.11.54. Epub 2011 Aug 10. Pharmacogenomics. 2011. PMID: 21830868

10

Oestrogen receptor-co-factor-chromatin specificity in the transcriptional regulation of breast cancer.

Zwart W, Theodorou V, Kok M, Canisius S, Linn S, Carroll JS. Zwart W, et al. Among authors: kok m. EMBO J. 2011 Oct 14;30(23):4764-76. doi: 10.1038/emboj.2011.368. EMBO J. 2011. PMID: 22002538 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

673 results

Search Page